目的 探討注射用甲磺酸酚妥拉明聯(lián)合硝苯地平緩釋片（Ⅱ）治療妊娠期高血壓的臨床療效。方法 選取2010年11月—2017年11月樂山市人民醫(yī)院收治的妊娠期高血壓患者76例為研究對象，利用Excel軟件隨機(jī)分為對照組和治療組，每組各38例。對照組口服硝苯地平緩釋片（Ⅱ），1片/次，2次/d。治療組在對照組的基礎(chǔ)上靜脈滴注注射用甲磺酸酚妥拉明，10 mg加入到5%葡萄糖注射液250 mL中，1次/d。兩組患者均連續(xù)治療10 d。觀察比較兩組的妊娠結(jié)局、血壓、24 h尿蛋白和血漿黏度。結(jié)果 治療后，治療組順產(chǎn)明顯高于對照組，而早產(chǎn)、死亡、窒息和宮內(nèi)窘迫顯著低于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P < 0.05）。治療后，兩組患者收縮壓和舒張壓均顯著下降，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P < 0.05）；且治療組患者的收縮壓和舒張壓均明顯低于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P < 0.05）。治療后，兩組24 h尿蛋白水平均顯著下降，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P < 0.05）；且治療組24 h尿蛋白水平明顯低于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P < 0.05）。治療后，兩組血漿黏度均顯著下降，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P < 0.05）；且治療組血漿黏度明顯低于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P < 0.05）。結(jié)論 注射用甲磺酸酚妥拉明聯(lián)合硝苯地平緩釋片（Ⅱ）治療妊娠期高血壓具有較好的臨床療效，能降低不良妊娠結(jié)局，控制血壓，降低24 h尿蛋白和血漿黏度，具有一定臨床推廣應(yīng)用價值。

Objective To investigate the clinical efficacy of Phentolamine Mesylate for injection combined with Nifedipine Sustained-release Tablets (Ⅱ) in treatment of gestational hypertension. Methods Patients (76 cases) with gestational hypertension in the People's Hospital of Leshan from November 2010 to November 2017 were randomly divided into control and treatment groups, and each group had 38 cases. Patients in the control group were po administered with Nifedipine Sustained-release Tablets (Ⅱ), 1 tablet/time, twice daily. Patients in the treatment group were iv administered with Phentolamine Mesylate for injection on the basis of the control group, 10 mg added into 5% glucose solution 250 mL, once daily. Patients in two groups were treated for 10 d. After treatment, pregnancy outcome, blood pressure, 24 h urine protein, and plasma viscosity in two groups were compared. Results After treatment, delivery in the treatment group was significantly higher than that in the control group, but preterm birth, death, asphyxia, and intrauterine distress of fetus in the treatment group was significantly lower than those in the control group, and there was difference between two groups (P < 0.05). After treatment, the systolic and diastolic pressures in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of 24 h urine protein in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the level of 24 h urine protein in the treatment group was significantly lower than that in the control group, with significant difference between two groups (P < 0.05). After treatment, the plasma viscosity in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the plasma viscosity in the treatment group was significantly lower than that in the control group, with significant difference between two groups (P < 0.05). Conclusion Phentolamine Mesylate for injection combined with Nifedipine Sustained-release Tablets (Ⅱ) has clinical curative effect in treatment of gestational hypertension, can decrease the adverse pregnancy outcomes, control blood pressure, and reduce the 24 h urinary protein and plasma viscosity level, which has a certain clinical application value.